WGS GeneDx Holdings Corp. Insider Trading

Director Eli Casdin buys 200,000 WGS shares for $11.1M across two days; stock down 69.7% from 52-week high but up 27.0% in 30 days.

Eli Casdin, a director, executed two separate purchases totaling 200,000 shares for $11,109,565.00, increasing his holdings from 3,507,164 shares to 3,707,164 shares. The purchases occurred at $56.44 on 2026-06-04 and $52.86 on 2026-06-05, with a blended average price of $55.55. This transaction is significant given the magnitude of capital deployed ($11.1M) and the current stock price of $51.80, placing the stock -69.7% from its 52-week high of $170.87 while it has recovered +27.0% over the past 30 days. At the same-ticker level, Casdin's prior four purchases at WGS were all well-timed (returning +19.2%, +22.6%, +22.7%, and +24.4% at the 90-day mark), though the single prior sale he executed at this ticker generated positive 90-day returns, indicating it was poorly-timed. The company posted revenue of $102,254,000.00 in its latest quarter with annual revenue growth of +40.0%, but remains unprofitable with net income of $-63,316,000.00 in its most recent full fiscal year—a context in which a director's substantial share purchase during a sharp drawdown warrants investor attention to the conviction or calculation behind the move.

Eli Casdin purchases 500,000 shares ($21.5M) across 3 transactions at GeneDx; stock down -73.8% from 52-week high, holdings rise to 3.51M shares (+16.6%).

Eli Casdin, Director at GeneDx Holdings Corp., executed 3 separate purchases totaling 500,000 shares for $21,459,735.50 ($21.5M) at a blended average price of $42.92 between May 18–20, 2026. The company is currently unprofitable with net income of $-63,316,000.00 on quarterly revenue of $102,254,000.00, though annual revenue growth reaches +40.0%. His prior 4 trades at this ticker were well-timed at the 90-day mark, yet the current stock price of $44.73 sits -73.8% from the 52-week high and -35.8% over the past 30 days, representing a sharp deterioration since his purchases. The scale and timing of this multi-transaction accumulation—adding 500,000 shares to raise holdings from 3,007,164 to 3,507,164 shares—occurs amid severe recent drawdown and negative earnings, warranting examination of whether this reflects conviction in the business fundamentals or other factors behind the insider's continued investment at WGS.

Director Meister buys 351,273 shares across 6 trades for $13.8M (avg $39.19) as stock falls 76.2% from 52-week high

Director Keith A. Meister executed 6 separate open-market purchases totaling 351,273 shares for $13,765,344.69 over three days (May 13–15, 2026), raising his holdings from 4,433,297 to 4,784,570 shares. The purchases occurred as the stock was in sharp decline, trading at $40.75 currently, which is -76.2% from the 52-week high of $170.87, and down -39.6% over the prior 30 days and -54.8% over 90 days. Across his 5 prior trades at WGS, Meister's timing outcomes were mixed: only 2 of 5 prior buys yielded positive 90-day returns. The company is unprofitable with net income of $-63,316,000.00 against revenue of $102,254,000.00 (latest quarter), though it shows annual revenue growth of +40.0%. The scale and timing of this multi-transaction purchase in a volatile, unprofitable biotech context warrant attention to underlying company conditions and Meister's conviction in the recovery thesis.

Director Meister acquires over 1.2M shares across 13 transactions; stock down 76% from 52-week high amid unprofitable operations and poor timing history at this ticker.

Keith Meister, a director and 10% beneficial owner of GeneDx, deployed substantial capital across 13 open-market purchases in early May, acquiring over 1.2 million shares at prices ranging from the mid-$35s to low-$41s. The stock is trading well below its 52-week high and has declined significantly over recent months, creating a classic "buying the dip" scenario. However, Meister's track record at this specific company is concerning: all five of his prior purchases at GeneDx in March yielded substantial subsequent declines over both the 30-day and 90-day periods that followed, and his broader insider track record across all securities shows minimal success with open-market buys. Additionally, GeneDx remains unprofitable with operating losses in its latest quarter despite year-over-year revenue growth, raising questions about whether the steep discount reflects genuine value or deteriorating fundamentals. This filing is notable primarily as a test of whether an insider with a poor historical timing record can successfully identify a bottom in a stock already down substantially from recent highs.

Director Keith A. Meister purchased 169,521 shares ($13.5M) at GeneDx across 10 transactions on 2026-03-03/05, raising holdings to 3.23M shares (+5.5%).

Director Meister executed 10 separate purchases totaling 169,521 shares for $13,460,089.63 at an average price of $79.40 over two trading days (2026-03-03 to 2026-03-05), significantly expanding a position already representing substantial company ownership. This transaction occurs as the stock trades at $82.00, down 51.0% from its 52-week high of $167.52 and down 13.9% over the past 30 days, yet Meister's prior trades at this ticker show a perfect 5 of 5 win rate at the 90-day mark with returns ranging from +84.0% to +94.6%. The company carries a negative full-year net income of $-7,635,000.00 despite strong revenue growth of 40.0% year-over-year, trading at a P/E of 71.93 on a $2.4B market cap. The scale and deliberate multi-tranche execution of this purchase, combined with Meister's consistent success timing WGS buys in the past, provides a meaningful signal regarding insider conviction during a period of significant stock weakness.

COO Bryan Dechairo sold 5,961 shares for $510,874.29 on 2026-02-04 under 10b5-1 plan

Bryan Dechairo, Chief Operating Officer of GeneDx Holdings Corp., executed 8 separate sales totaling 5,961 shares for $510,874.29 on 2026-02-04, at a blended average price of $85.70. The transaction reduced his holdings to zero shares, representing a complete liquidation of his position. This sale was executed under a pre-arranged 10b5-1 trading plan adopted on 2025-09-15, meaning the timing and volume were scheduled in advance rather than discretionary. The complete elimination of the COO's shareholding in a single scheduled transaction is notable and warrants investor attention to understand whether the plan reflects prior confidence in valuations or other strategic considerations at the time of adoption.

Director Joshua Ruch sold 38,000 shares (38.0K) of WGS across 15 separate transactions on 2025-11-24 for $6,093,967.44, reducing holdings by 24.0%

Joshua Ruch, a Director at GeneDx Holdings, executed 15 separate sales totaling 38,000 shares (38.0K shares) for $6,093,967.44 ($6.1M) on 2025-11-24 at a blended average price of $160.37, reducing his stake from 158,083 to 120,083 shares (a 24.0% reduction of pre-transaction holdings). The stock was trading near its 52-week high at $165.61, only 1.1% below the $167.52 peak, and has appreciated significantly over the 30-day (+26.8%) and 90-day (+28.4%) periods. This large single-day sale by a director is material in absolute dollar terms ($6.1M) and represents a substantial change in the director's disclosed position. The company remains unprofitable on a full-year basis (net income $-7.6M), although recent quarterly revenue of $116.7M reflects 50.8% annual growth, highlighting a disconnect between financial performance trajectory and current valuation (P/E of 2365.86).

CFO Kevin Feeley sells 6,609 shares for $716,260.64 at GeneDx (WGS) via 10b5-1 plan adopted Aug 2024

Kevin Feeley, CFO of GeneDx Holdings Corp., executed 7 separate sales totaling 6,609 shares for $716,260.64 on 2025-09-30 across a range of prices from $105.24 to $113.68 per share. This transaction reduces his holdings from 10,001 shares to 3,392 shares. The sales are part of a pre-arranged 10b5-1 trading plan adopted on 2024-08-21, meaning the timing and pricing are scheduled rather than discretionary. The large volume reduction reflects execution of a predetermined systematic disposal plan rather than a market-responsive decision.

GeneDx CEO Katherine Stueland sold 12,858 shares for $1,390,911.39 under 10b5-1 plan

Katherine Stueland, GeneDx CEO, executed 8 separate sales totaling 12,858 shares for $1,390,911.39 across a single trading date at prices ranging from $105.10 to $113.68. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2024-08-16, meaning the sales were scheduled and not discretionary. Post-transaction, Stueland retains 1,720 shares, representing an 88.2% reduction in her prior holding of 14,578 shares. The large position reduction warrants investor attention regarding executive confidence in the company's direction going forward.

Director Ryan Jason sold 39,222 shares for $4,995,800.61 at GeneDx (WGS), reducing stake by 76.7% on trading day to $129.19 high

Ryan Jason, a Director at GeneDx Holdings, executed 7 separate sales totaling 39,222 shares for $4,995,800.61 on 2025-08-27, reducing his holdings from 51,126 to 11,904 shares (a 76.7% reduction). The sales occurred across a narrow price band ($125.07–$130.01 blended average $127.37), and the current price of $129.19 is at the 52-week high with stock up 52.2% in 30 days and 84.6% in 90 days. Notably, his 5 prior sales at WGS over the past nine months generated all positive 90-day returns (+5.7% to +65.0%), with 0 of 5 being well-timed (all occurred before subsequent gains), suggesting a consistent pattern of selling before further appreciation. Given the company's recent exceptional growth trajectory (90-day +84.6%, annual revenue growth +50.8%) and the outsized valuation (P/E 2583.80), the scale and timing of this sale warrant attention as context for current price trajectory.